New drug trial aims to slow silent kidney damage
NCT ID NCT07146906
Summary
This study is testing whether an investigational drug called zigakibart can slow the progression of IgA nephropathy, a kidney disease. It will involve 32 adults who will receive the drug for two years while researchers check their kidney tissue and function. The main goal is to see if the treatment reduces harmful protein deposits and inflammation in the kidneys.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN A NEPHROPATHY (IGAN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.